How We Break Through
Our team is on a mission to deliver transformative outcomes for people with cancer by breaking through the frontiers of immuno-oncology research.
We seek to substantially increase response rates, response quality and durability, and long-term survival through the unique Surface approach to our research.
The knowledge and experience of our world-class scientific advisors informs every part of our work through a uniquely collaborative process that emphasizes collective learning.
Each new insight is a valuable opportunity to refine our approach and apply insights to identify new biology and bring forward increasingly optimized therapeutic antibody candidates.
Cancer acts to suppress both innate and adaptive immune activity, so the Surface team focuses on candidates designed to impact both arms of the immune response.
We prioritize versatility and use multiple proven platforms to characterize new therapeutic antibody candidates and inform rapid decision making to the benefit of our overall development portfolio.
Our Pipeline of Investigational Therapies
Surface is developing multiple antibody immunotherapy candidates focused on enhancing the innate and adaptive immune responses to enable a robust immunologic response and enhance outcomes for patients with cancer.
Surface’s pipeline spans compelling areas of discovery and development across four key areas of immune modulators to: activate both macrophages and natural killer cells, inhibit or deplete regulatory T cells and block suppressive cell signaling molecules, including cytokines and metabolites.
Posters & Publications
The Surface team is committed to scientific exchange and continual learning, from each other, from our work and from experts around the world, to break through scientific challenges.